Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are often present in newly
diagnosed acute myeloid leukemia (AML) patients with an incidence rate of approximately …

Despite some advances in targeted therapeutics of human cancers, curative cancer
treatment still remains a tremendous challenge due to the occurrence of drug resistance. A …

Simple Summary AML is a highly heterogeneous hematological disease and is the second
most common form of leukemia. Around 40% of AML patients display elevated nuclear NF …

Simple Summary FLT3 mutation is commonly present in newly diagnosed patients with
acute myeloid leukemia, and confers high relapse risk. Targeted therapies with FLT3 …

Simple Summary Despite the recent approval of some FLT3 inhibitors by drug regulatory
agencies, treatment guidelines for FLT3-mutated AML still require allogeneic transplantation …

In this review, we analyse the impact of oncogenic Ras mutations in mediating cancer drug
resistance and the progress made in the abrogation of this resistance, through …

FMS-like tyrosine kinase 3 (FLT3) is mutated in approximately 30% of acute myeloid
leukemia (AML) patients. The presence of FLT3-ITD (internal tandem duplication, 20–25%) …

Background Chromosome translocations involving mixed lineage leukemia 1 (MLL1) cause
acute leukemia in most infants and 5–10% children/adults with dismal clinical outcomes …

New treatment options of acute myeloid leukemia (AML) are rapidly emerging. Pre-clinical
models such as ex vivo cultures are extensively used towards the development of novel …

Despite incredible progress in cancer treatment, therapy resistance remains the leading
limiting factor for long-term survival. During drug treatment, several genes are …